Education
About Us
Working with TipRanks
Follow Us
Boundless Bio Inc. (BOLD)
NASDAQ:BOLD
BOLD Stock Chart & Stats
$1.26
-$0.03(-1.15%)
At close: 4:00 PM EST
$1.26
-$0.03(-1.15%)
Day’s Range― - ―
52-Week Range$1.00 - $2.77
Previous CloseN/A
Volume5.57K
Average Volume (3M)178.65K
Market Cap
$28.21M
Enterprise Value-$40.28M
Total Cash (Recent Filing)$117.57M
Total Debt (Recent Filing)$49.76M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Mar 26, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding22,385,610
10 Day Avg. Volume162,533
30 Day Avg. Volume178,649
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit64.24
Enterprise Value/Ebitda0.63
Forecast
1Y Price Target
$4.00Price Target Upside217.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe BBI-355 (CHK1) / BBI-825 (RNR) combo arm in the POTENTIATE trial is open for enrollment, suggesting potential data in 2026.
Efficacy And SafetyCHK1i + RNRi could achieve meaningful efficacy at tolerable exposures, avoiding the tox ceiling that crippled prior CHK1s.
Financial OutlookThe company reported $127mn in cash reiterating runway into 1H28, and expects PoC clinical readouts for both programs within this timeline.
Bears Say
Past Trial LimitationsPrior trials combined a CHK1 inhibitor and subtherapeutic gemcitabine and demonstrated responses in multiple tumor types, but were limited by hematological toxicities.
Price Target ReductionThe company reported a reduction in price target from $5 to $4 per share.
Boundless Bio Inc. News
BOLD FAQ
What was Boundless Bio Inc.’s price range in the past 12 months?
Boundless Bio Inc. lowest stock price was $1.00 and its highest was $2.77 in the past 12 months.
What is Boundless Bio Inc.’s market cap?
Boundless Bio Inc.’s market cap is $28.21M.
When is Boundless Bio Inc.’s upcoming earnings report date?
Boundless Bio Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 69 days.
How were Boundless Bio Inc.’s earnings last quarter?
Boundless Bio Inc. released its earnings results on Nov 05, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.582 by -$0.038.
Is Boundless Bio Inc. overvalued?
According to Wall Street analysts Boundless Bio Inc.’s price is currently Undervalued.
Does Boundless Bio Inc. pay dividends?
Boundless Bio Inc. does not currently pay dividends.
What is Boundless Bio Inc.’s EPS estimate?
Boundless Bio Inc.’s EPS estimate is -0.52.
How many shares outstanding does Boundless Bio Inc. have?
Boundless Bio Inc. has 22,385,610 shares outstanding.
What happened to Boundless Bio Inc.’s price movement after its last earnings report?
Boundless Bio Inc. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.582. Following the earnings report the stock price went down -3.077%.
Which hedge fund is a major shareholder of Boundless Bio Inc.?
Currently, no hedge funds are holding shares in BOLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boundless Bio Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
BOLD Stock 12 Month Forecast
Average Price Target
$4.00
▲(217.46% Upside)
Technical Analysis
Pluri
―
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
Barinthus Biotherapeutics
―
Ownership Overview
8.20%
Insiders
10.66% Mutual Funds
15.10% Other Institutional Investors
63.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---